273 related articles for article (PubMed ID: 25184177)
1. Apixaban: a new direct oral anticoagulant for stroke prevention in atrial fibrillation.
Hohnloser SH
Eur Heart J; 2014 Jul; 35(28):1828-9. PubMed ID: 25184177
[TBL] [Abstract][Full Text] [Related]
2. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
3. Apixaban to prevent stroke in patients with atrial fibrillation: a review.
Peterson BE; Al-Khatib SM; Granger CB
Ther Adv Cardiovasc Dis; 2017 Mar; 11(3):91-104. PubMed ID: 27342651
[TBL] [Abstract][Full Text] [Related]
4. Which oral anticoagulant for atrial fibrillation.
Med Lett Drugs Ther; 2016 Apr; 58(1492):45-6. PubMed ID: 27049507
[No Abstract] [Full Text] [Related]
5. Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial.
Coppens M; Synhorst D; Eikelboom JW; Yusuf S; Shestakovska O; Connolly SJ
Eur Heart J; 2014 Jul; 35(28):1856-63. PubMed ID: 24569032
[TBL] [Abstract][Full Text] [Related]
6. Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon.
Kaess BM; Ammar S; Reents T; Dillier R; Lennerz C; Semmler V; Grebmer C; Bourier F; Buiatti A; Kolb C; Deisenhofer I; Hessling G
Am J Cardiol; 2015 Jan; 115(1):47-51. PubMed ID: 25456870
[TBL] [Abstract][Full Text] [Related]
7. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
8. New Advances in Atrial Fibrillation Management: The Role of Apixaban.
Rosano GMC; Spoletini I; Gianni W; Vitale C
Curr Drug Targets; 2018; 19(6):585-592. PubMed ID: 29034832
[TBL] [Abstract][Full Text] [Related]
9. A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE.
Hess CN; Al-Khatib SM; Granger CB; Lopes R
Expert Rev Cardiovasc Ther; 2013 Sep; 11(9):1105-14. PubMed ID: 23992517
[TBL] [Abstract][Full Text] [Related]
10. Apixaban (Eliquis)--a new oral anticoagulant for atrial fibrillation.
Med Lett Drugs Ther; 2013 Feb; 55(1409):9-10. PubMed ID: 23381226
[No Abstract] [Full Text] [Related]
11. Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.
Yates SW
Hosp Pract (1995); 2011 Oct; 39(4):7-16. PubMed ID: 22056819
[TBL] [Abstract][Full Text] [Related]
12. Apixaban: a new factor Xa inhibitor for stroke prevention in patients with nonvalvular atrial fibrillation.
Lam S
Cardiol Rev; 2013; 21(4):207-12. PubMed ID: 23535530
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and Safety of Apixaban Versus Rivaroxaban for Patients With Atrial Fibrillation.
Ann Intern Med; 2020 Apr; 172(7):. PubMed ID: 32150747
[No Abstract] [Full Text] [Related]
15. Quick reference guide to apixaban.
Hurst KV; O'Callaghan JM; Handa A
Vasc Health Risk Manag; 2017; 13():263-267. PubMed ID: 28744136
[TBL] [Abstract][Full Text] [Related]
16. Prescribing of Direct Oral Anticoagulants in Atrial Fibrillation Based on Estimation of Renal Function Using Standard and Modified Cockcroft-Gault Equations: A Retrospective Analysis.
Kucey M; Bolt J; Albers L; Bell A; Iroh N; Toppings J
Can J Hosp Pharm; 2016; 69(5):409-414. PubMed ID: 27826159
[No Abstract] [Full Text] [Related]
17. Apixaban for the prevention of stroke in atrial fibrillation.
Littrell R; Flaker G
Expert Rev Cardiovasc Ther; 2012 Feb; 10(2):143-9. PubMed ID: 22292869
[TBL] [Abstract][Full Text] [Related]
18. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.
Eikelboom JW; O'Donnell M; Yusuf S; Diaz R; Flaker G; Hart R; Hohnloser S; Joyner C; Lawrence J; Pais P; Pogue J; Synhorst D; Connolly SJ
Am Heart J; 2010 Mar; 159(3):348-353.e1. PubMed ID: 20211294
[TBL] [Abstract][Full Text] [Related]
19. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
[TBL] [Abstract][Full Text] [Related]
20. Plasma Apixaban Levels in Patients Treated Off Label With the Lower Dose.
Bhagirath VC; Chan N; Hirsh J; Ginsberg J; de Vries TAC; Eikelboom J
J Am Coll Cardiol; 2020 Dec; 76(24):2906-2907. PubMed ID: 33303080
[No Abstract] [Full Text] [Related]
[Next] [New Search]
